Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | BMX | P51813 | 4/20 | 0.39 |
| ▸ | ITK | Q08881 | 4/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008617 | 1.00 | BTK (0.39) | BTKEGFRBMXITKMTOR | |
| SCHEMBL30855178 | 0.91 | BTK (0.36) | BTKEGFRBMXITKMTOR | |
| SCHEMBL29333566 | 0.91 | BTK (0.36) | BTKEGFRBMXITKMTOR | |
| SCHEMBL29333484 | 0.90 | BTK (0.38) | BTKEGFRBMXITKMTOR | |
| SCHEMBL31224415 | 0.90 | MTOR (0.37) | BTKEGFRBMXITKMTOR | |
| SCHEMBL31223749 | 0.90 | MTOR (0.37) | BTKEGFRBMXITKMTOR | |
| SCHEMBL31223698 | 0.90 | MTOR (0.37) | BTKEGFRBMXITKMTOR | |
| SCHEMBL29333508 | 0.89 | CCNC (0.38) | BTKEGFRBMXITKCCNC | |
| SCHEMBL31008642 | 0.89 | CCNC (0.38) | BTKEGFRBMXITKCCNC | |
| SCHEMBL29333552 | 0.87 | MAPK1 (0.40) | BTKEGFRBMXITKCCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | BTK 3290/4885EGFR 4004/4885BMX 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.